Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 16/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17940522 | 0.99 | KDM4E (0.51) | MCHR1HTR2AHTR2CKDM4EALOX15 | |
| SCHEMBL16602558 | 0.88 | HTR2A (0.50) | MCHR1HTR2AHTR2CKDM4EALOX15 | |
| SCHEMBL21153968 | 0.88 | MCHR1 (0.53) | MCHR1HTR2AHTR2CKDM4EALOX15 | |
| SCHEMBL18404827 | 0.84 | MCHR1 (0.52) | MCHR1HTR2AHTR2CKDM4EALOX15 | |
| SCHEMBL3477565 | 0.82 | MCHR1 (0.51) | MCHR1HTR2AHTR2CKDM4EALOX15 | |
| SCHEMBL20883916 | 0.80 | MCHR1 (0.50) | MCHR1HTR2AHTR2CKDM4EALOX15 | |
| SCHEMBL20884616 | 0.80 | MCHR1 (0.49) | MCHR1HTR2AHTR2CKDM4EALOX15 | |
| SCHEMBL25685286 | 0.79 | PARP1 (0.42) | MCHR1HTR2AHTR2CKDM4EALOX15 | |
| SCHEMBL15977191 | 0.78 | MCHR1 (0.81) | MCHR1 | |
| SCHEMBL967629 | 0.78 | HTR2C (0.79) | MCHR1HTR2AHTR2CKDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2023-08-17 | — | — | US | disclosed |
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2023-08-17 | — | — | US | disclosed |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | AC IMMUNE SA (CH) | 2023-06-27 | — | — | US | disclosed |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | AC IMMUNE SA (CH) | 2023-06-27 | — | — | US | disclosed |
| WO-2019233883-A1 | TETRAHYDROBENZOFURO[2,3-C]PYRIDINE AND BETA-CARBOLINE COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES | AC IMMUNE SA (CH) | 2019-12-12 | — | — | WO | disclosed |
| US-9630964-B2 | Fluoro-9-methyl-β-carbolines | AUDIOCURE PHARMA GMBH (DE) | 2017-04-25 | — | — | US | disclosed |
| US-9630964-B2 | Fluoro-9-methyl-β-carbolines | AUDIOCURE PHARMA GMBH (DE) | 2017-04-25 | — | — | US | disclosed |
| US-9630964-B2 | Fluoro-9-methyl-β-carbolines | AUDIOCURE PHARMA GMBH (DE) | 2017-04-25 | — | — | US | disclosed |
| EP-2941429-B1 | FLUOR-9-METHYL-BETA-CARBOLINES | AUDIOCURE PHARMA GMBH (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-2941429-B1 | FLUOR-9-METHYL-BETA-CARBOLINES | AUDIOCURE PHARMA GMBH (DE) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015044434-A9 | FLUOR-9-METHYL-Β-CARBOLINES | AUDIOCURE PHARMA GMBH (DE) | 2016-08-25 | — | — | WO | disclosed |
| US-20160214981-A1 | FLUORO-9-METHYL-BETA-CARBOLINES | AUDIOCURE PHARMA GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| US-20160214981-A1 | FLUORO-9-METHYL-BETA-CARBOLINES | AUDIOCURE PHARMA GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| US-20160214981-A1 | FLUORO-9-METHYL-BETA-CARBOLINES | AUDIOCURE PHARMA GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| CN-105579455-A | Fluor-9-methyl-[beta]-carbolines | AUDIOCURE PHARMA GMBH | 2016-05-11 | — | — | CN | disclosed |
| WO-2015044434-A2 | FLUOR-9-METHYL-Β-CARBOLINES | AUDIOCURE PHARMA GMBH (DE) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | MCHR1 2694/4885HTR2A 2941/4885HTR2C 3649/4885 |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | MAPT, PSEN2, PSEN1 | MCHR1 3114/4885HTR2A 3030/4885HTR2C 3776/4885 |
| US-20160214981-A1 | FLUORO-9-METHYL-BETA-CARBOLINES | CHRNA9, COMT, CHRM3 | MCHR1 1719/4885HTR2A 159/4885HTR2C 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.